

3-D mammography significantly reduces breast biopsy rates

March 19 2019



Images in a 63-year-old asymptomatic woman who was recalled because a new 8-mm mass was detected in the left breast at screening mam¬mography. (a) Left mediolateral oblique and (b) left mediolateral oblique spot compression mammograms show an 8-mm partly ill-defined mass (arrow) in the upper breast. (c) Left mediolateral oblique digital breast tomosynthesis (DBT) image shows an 8-mm well-defined mass (arrow) in the upper breast. The mass was interpreted as benign at DBT and was coded R2 benign; however, it was indeterminate at full-field digital mammography. Targeted US of the breast revealed normal findings, and stereotactic biopsy yielded a diagnosis of micropapillary ductal carcinoma in situ (DCIS). Wide local surgical exci¬sion revealed a 5-mm high-grade DCIS. Credit: Radiological Society of North America



The use of digital breast tomosynthesis (DBT), also known as 3-D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study published in the journal *Radiology*.

Unlike standard or full-field digital mammography (FFDM), which captures two X-ray images of the breast from top-to-bottom and from side-to-side, DBT captures multiple images from different angles that are synthesized into 3-D images by a computer.

"The thin slice images of the breast taken with DBT reduce the effect of tissue overlap, which often leads to cancers being missed or to women who don't have <u>breast cancer</u> being recalled for <u>diagnostic imaging</u>," said lead researcher Nisha Sharma, M.B.Ch.B., director of breast <u>screening</u> and clinical lead for breast imaging at Leeds Teaching Hospital NHS Trust, Seacroft Hospital, in Leeds, England. "In our study, we wanted to determine the impact of DBT on the <u>biopsy</u> rate among women recalled for an abnormal screening mammogram."

The single-institution prospective study included 30,933 women who had a screening FFDM or screening breast MRI through the U.K.'s National Health Service Breast Screening Programme (NHSBSP) at Seacroft Hospital between 2015 and 2016. Within six weeks of their breast screening, the women also underwent DBT.





Images in a 46-year-old asymptomatic woman who was recalled for asymmetry in the right breast that was assessed as benign on further diagnostic mammograms and in whom targeted US findings were normal. Full-field digital mammography findings were false negative, and biopsy re¬vealed intermediate ductal carcinoma in situ. (a) Right mediolateral oblique (MLO) and (b) lateral views. (c) Right MLO digital breast tomosynthesis (DBT) image shows an indeterminate spiculated density that was coded R3 indeterminate. Stereotacticguided DBT biopsy was performed and revealed a papil¬loma with atypia. The patient underwent surgical diagnostic biopsy, which showed a 4-mm intermediate-grade ductal carcinoma in situ. Credit: Radiological Society of North America

Of the study group, 1,470 women were recalled for further imaging (4.8 percent recall rate) to assess an abnormality. A final recall group of 827 women after exclusions (mean age 56.7 years) required 571 biopsies, yielding a biopsy rate of 69 percent. Biopsy detected 142 cancers. In 429 of the biopsies performed, the suspicious lesion detected on screening mammography was not cancerous, for a benign biopsy rate of 75



percent.

The researchers read the DBT images blinded to the original FFDM screening results to determine whether 3-D images would have influenced the biopsy recommendation. The inclusion of DBT imaging would have reduced the number of biopsies performed on recalled women from 571 to 298—while still detecting the 142 cancers—for a biopsy rate of 36 percent, and a benign biopsy rate of 52 percent.

"DBT allows for improved reader accuracy and confidence in determining if a mammographic abnormality is concerning or not, leading to a reduction in the number of biopsies performed," Dr. Sharma said. "Our study validates that DBT can help in the diagnostic workup of mammographic abnormalities and reduce harm to <u>women</u> through fewer false positive biopsies without any reduction in the <u>cancer</u> detection rate."

More information: "The Potential Impact of Digital Breast Tomosynthesis on the Benign Biopsy Rate in Women Recalled within the UK Breast Screening Programme" *Radiology*, 2019.

Provided by Radiological Society of North America

Citation: 3-D mammography significantly reduces breast biopsy rates (2019, March 19) retrieved 5 May 2024 from https://medicalxpress.com/news/2019-03-d-mammography-significantly-breast-biopsy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.